🔎 Trials Near Me

ホーム › 前立腺がん › オハイオ

オハイオにおける前立腺がんの臨床試験

オハイオ内の拠点で、前立腺がんに関する65件の研究が参加者を募集しています。

オハイオ内の都市

公式研究テキスト(英語)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • The Cleveland Clinic Taussig Cancer Center, Cleveland
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  • Aultman Health Foundation, Canton
  • Ohio State University Comprehensive Cancer Center, Columbus
  • ProMedica Flower Hospital, Sylvania
被験者募集中第3相
18歳以上 · 男性 · 2026/10/02更新 · NCT06931340

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  • MetroHealth Medical Center, Cleveland
被験者募集中第3相
18歳以上 · 男性 · 2026/10/02更新 · NCT07200830

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton
  • 他44件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  • MetroHealth Medical Center, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06632977

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

  • Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Cente, Cleveland
被験者募集中第2相
19歳以上 · 全性別 · 2026/10/02更新 · NCT06738303

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Strecker Cancer Center-Belpre, Belpre
  • Adena Regional Medical Center, Chillicothe
  • Ohio State University Comprehensive Cancer Center, Columbus
  • 他22件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

  • University Hospitals Cleveland Medical Center, Cleveland
被験者募集中
18歳以上 · 男性 · 2026/09/28更新 · NCT06496256

DESTINY-PANTUMOUR04

  • Research Site, Canton
  • Research Site, Maumee
被験者募集中観察研究
18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

  • University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07319871

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  • University Hospitals Cleveland Medical Center ( Site 0043), Cleveland
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06136650

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

  • University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1相
18歳以上 · 男性 · 2026/09/25更新 · NCT07082920

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  • University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
  • TriState Urologic Services PSC Inc. dba The Urology Group, Cincinnati
  • University Hospitals Cleveland Medical Center, Cleveland
  • 他2件
被験者募集中第3相
18歳以上 · 男性 · 2026/09/24更新 · NCT07028853

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • Oncology Hematology Care Incorporated, Cincinnati
  • The Ohio State University, Columbus
  • Dayton Physicians LLC Dayton, Dayton
被験者募集中第3相
18歳以上 · 男性 · 2026/09/22更新 · NCT07213674

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  • Urology Group - Solaris Network, Cincinnati
  • Central Ohio Urology Group, Gahanna
被験者募集中第3相
18歳〜100歳 · 男性 · 2026/09/22更新 · NCT06855277

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  • Research Site, Columbus
被験者募集中第3相
18歳以上 · 男性 · 2026/09/18更新 · NCT06952803

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0061), Columbus
被験者募集中第3相
18歳以上 · 男性 · 2026/09/17更新 · NCT06925737

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

  • University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
被験者募集中第2相
18歳以上 · 男性 · 2026/09/15更新 · NCT06150417

Investigation of Impact of AI on Prostate Cancer Workflow

  • Cleveland Clinic Foundation, Cleveland
被験者募集中
55歳〜80歳 · 全性別 · 2026/09/15更新 · NCT07084779

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

  • Oncology Hematology Care Incorporated, Cincinnati
被験者募集中第1相
18歳以上 · 男性 · 2026/09/15更新 · NCT07493512

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

  • University Hospitals Cleveland, Cleveland
被験者募集中
18歳以上 · 男性 · 2026/09/14更新 · NCT06511141

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  • Cleveland Clinic Akron General, Akron
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • 他27件
被験者募集中第3相
18歳以上 · 男性 · 2026/09/10更新 · NCT05946213

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  • Solaris Health - The Urology Group, Cincinnati
被験者募集中第2相
18歳以上 · 男性 · 2026/09/03更新 · NCT07005154

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  • Gabrail Cancer Center Research, Canton
被験者募集中第3相
18歳以上 · 男性 · 2026/09/03更新 · NCT07723248

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Louis Stokes Cleveland VA Medical Center, Cleveland
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  • Research Site, Cleveland
  • Research Site, Dayton
被験者募集中第3相
18歳以上 · 男性 · 2026/08/26更新 · NCT07611110

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  • Oncology Hematology Care Incorporated, Cincinnati
被験者募集中第1相
18歳以上 · 男性 · 2026/08/21更新 · NCT04221542

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

  • The Ohio State University, Columbus
  • Taylor Cancer Research Center, Maumee
被験者募集中第1/2相
18歳以上 · 男性 · 2026/08/20更新 · NCT06785636

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • Good Samaritan Hospital - Cincinnati, Cincinnati
  • Bethesda North Hospital, Cincinnati
  • Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第3相
18歳以上 · 男性 · 2026/08/19更新 · NCT04423211

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第2相
18歳以上 · 男性 · 2026/08/17更新 · NCT06842498

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
  • Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  • University of Cincinnati Medical Center, Cincinnati
  • The Ohio State University, Columbus
被験者募集中第1相
18歳〜100歳 · 男性 · 2026/08/13更新 · NCT05519449

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

  • Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland
被験者募集中
19歳以上 · 男性 · 2026/08/06更新 · NCT05610852

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

  • The Ohio State University, Columbus
被験者募集中第1相
18歳以上 · 男性 · 2026/07/31更新 · NCT06613100

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  • Cleveland Clinic Akron General, Akron
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • 他15件
被験者募集中第3相
18歳以上 · 男性 · 2026/07/14更新 · NCT06592924

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

  • Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 男性 · 2026/07/14更新 · NCT05691465

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

  • The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 男性 · 2026/07/09更新 · NCT07103018

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

  • Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland
被験者募集中観察研究
18歳以上 · 男性 · 2026/07/07更新 · NCT07406282

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。